The Journal of Pediatrics
Volume 153, Issue 5 , Pages 663-666 , November 2008

Effect of Domperidone on QT Interval in Neonates

Received 21 September 2007 ,Revised 2 April 2008 ,Accepted 7 May 2008.

References 

  1. Tahiri C. Prépulsid et allongement de l'espace QT. J Pédiatr Puériculture. 1998;11:422–428
  2. Lupoglazoff JM, Bedu A, Faure C, Denjoy I, Casasoprana A, Cézard JP, et al. Allongement de l'espace QT sous cisapride chez le nouveau-né et le nourrisson. Arch Pédiatr. 1997;4:509–514
  3. Hanson R, Browne G, Fasher B, Mcaskill M, Moroney P, Hawker R. Cisapride-induced prolonged QT interval: too much of a good thing!. J Pediatr. 1997;130:164–166
  4. Wysowski D, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996;335:4
  5. Abildskov JA. The prolonged QT interval. Ann Rev Med. 1979;30:171–179
  6. Alimurung M, Joseph L, Graige E, Massell BF. The Q-T interval in normal infants and children. Circulation. 1950;1:1329–1337
  7. Lepeschkin E, Surawicz B. The measurement of the QT interval of the Electrocardiogram. Circulation. 1952;6:378–388
  8. Savelieva I, Yi G, Guo X, Hnatkova K, Malik M. Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion. Am J Cardiol. 1998;81:471–477
  9. Rocha C, Barbosa M. QT interval prolongation associated with the oral use of Dompéridone in an infant. Pediatr Cardiol. 2005;26:720–723
  10. Morganroth J. Relations of QTc prolongation on electrocardiogram to torsades de pointes: definitions and mechanisms. Am J Cardiol. 1993;72:10B–13B
  11. Bruera E, Villamayor R, Roca E, Barugel M, Tronge J, Chacon R. QT interval prolongation and ventricular fibrillation with IV domperidone. Cancer Treat Rep. 1986;70:545–546
  12. Quinn N, Parkes D, Jackson G, Upward J. Cardiotoxicity of domperidone. Lancet. 1985;2:724
  13. Wang SH, Lin CY, Huang TY, Wu WS, Chen CC, Tsai SH. QT interval effects of cisapride in the clinical setting. Inter J Cardiol. 2001;80:179–183
  14. Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation. 2000;102:1883–1885
  15. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs. Medicine. 2003;82:282–290
  16. Yang T, Snyders D, Roden D. Drug block of Ikr: model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol. 2001;38:737–744
  17. Committee for Proprietary Medicinal Products. The Assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. 1997;986–996
  18. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man, IV: the pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;61:61–70
  19. Huizing G, Brouwers JR, Westhuis P. Plasma drug concentration and prolactin release after acute and subchronic oral administration of domperidone and metoclopramide: the serum concentration of drugs. 1980;271–277
  20. Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, et al. Genetically defined therapy of inherited long-QT syndrome: correction of abnormal repolarization by potassium. Circulation. 1996;94:1018–1022
  21. Dubin A, Kikkert M, Mirmiran M, Ariagno R. Cisapride associated with QTc prolongation in very low birth weight preterm infants. Pediatrics. 2001;107:1313–1316
  22. Zamora SA, Belli DC, Friedli B, Jaeggi E. 24-hours electrocardiogram before and during cisapride treatment in neonates and infants. Biol Neonate. 2004;85:229–236

 The authors declare no conflict of interest.

PII: S0022-3476(08)00397-1

doi: 10.1016/j.jpeds.2008.05.013

The Journal of Pediatrics
Volume 153, Issue 5 , Pages 663-666 , November 2008

Article Tools

* Image Usage & Resolution